admin

In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT Novo Nordisk’s new manufacturing facility in Clayton, North Carolina. Courtesy: Novo Nordisk Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug
0 Comments
Ongoing problems with the new Free Application for Federal Student Aid have delayed financial aid award letters — and have even prevented many high school seniors and their families from applying for aid at all. As of June 14, only 45% of the high school class of 2024 has completed the FAFSA, according to the National College Attainment Network.
0 Comments
Reining in America’s $3.3 Trillion Tax-Exempt Economy Skip to content Table of Contents Key Findings For over a century, lawmakers have exempted politically favored organizations and industries from the taxA tax is a mandatory payment or charge collected by local, state, and national governments from individuals or businesses to cover the costs of general government
0 Comments
The Shein logo can be seen on a smartphone, while the Chinese online retailer’s website is open on a laptop.  Monika Skolimowska | Picture Alliance | Getty Images China-founded e-commerce company Shein’s hopes of going public in the United States are growing slimmer by the day, according to experts, as rising tensions between Beijing and
0 Comments
In this article ADSK Follow your favorite stocksCREATE FREE ACCOUNT Igor Golovniov | Lightrocket | Getty Images Company: Autodesk (ADSK) Business: Autodesk engages in three-dimensional (3D) design, engineering and entertainment technology solutions. Its product offerings are focused on the following categories: Architecture, Engineering and Construction, AutoCAD and AutoCAD LT, Manufacturing, and Media and Entertainment. Its
0 Comments
In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related
0 Comments